Articles
| Open Access |
DOI: CLINICAL CASE OF MULTISYSTEM ATROPHY WITH PARKINSONISM
Naira F. Aripova , Researcher Tashkent Pediatric Medical Institute, Uzbekistan Umida T. Omonova , Researcher Tashkent Pediatric Medical Institute, UzbekistanAbstract
Multiple system atrophy (MSA) is a steadily progressive neurodegenerative disease involving the pyramidal system, cerebellum, and autonomic nervous systemх[1]. MSA is an α-synucleinopathy with specific glioneuronal degeneration involving striatonigral, olivopontocerebellar, and autonomic nervous systems but also other parts of the central and peripheral nervous systems[3]. Clinical manifestations include hypotension, urinary retention, constipation, ataxia, parkinsonism, and postural instability. Multiple system atrophy affects both men and women equally, the first symptoms usually appear after age 53. The etiology of this pathology is unknown, but is associated with the accumulation of bodies containing alpha-synuclein in different parts of the brain[1]. There are two types of MSA. The first type occurs with a predominance of cerebellar dysfunctions: ataxia, postural instability. In the clinical setting of the second type of MSA, symptoms of parkinsonism predominate, such as muscle rigidity, bradykinesia, postural disturbances, non-resting tremor and dysarthria. Also, both types exhibit autonomic disorders. The prognosis for this pathology is unfavorable; after the first symptoms appear, life expectancy is 9-10 years.
Keywords
Multiple system atrophy (MSA), ataxia, parkinsonism
References
Poewe W, Stankovic I, Halliday G, Meissner WG, Wenning GK, Pellecchia MT, Seppi K, Palma JA, Kaufmann H. Multiple system atrophy. Nat Rev Dis Primers. 2022 Aug 25;8(1):56. doi: 10.1038/s41572-022-00382-6. PMID: 36008429.
Jellinger KA. Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1. J Alzheimers Dis. 2018;62(3):1141-1179. doi: 10.3233/JAD-170397. PMID: 28984582; PMCID: PMC5870010.
Kim M., Ahn J.H., Cho Y. et al. Differential value of brain magnetic resonance imaging in multiple system atrophy cerebellar phenotype and spinocerebellar ataxias. Sci. Rep. 2019; 9(1): 1–7. DOI: 10.1038/s41598-019-53980-y
Beliveau V., Krismer F., Skalla E. et al. Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. Parkinsonism Relat. Disord. 2021; 85: 30–36.
Cong S., Xiang C., Wang H., Cong S. Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. J. Neurol. 2021; 268: 2703–2712. DOI: 10.1007/s00415-020-09781-9
Article Statistics
Copyright License
Copyright (c) 2024 Naira F. Aripova, Umida T. Omonova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.